Form 4: Paychex Director Kevin Price Receives Equity Award
Insider Transaction Report
Paychex Director Kevin A. Price was granted 725 restricted stock units and 3,061 stock options as part of the company's incentive plan.
Summary
- Kevin A. Price, a Director of Paychex Inc. (PAYX), acquired 725 shares of Common Stock in the form of restricted stock units (RSUs) on October 15, 2025.
- These RSUs were awarded at a price of $0 and are subject to vesting, pursuant to the Amended and Restated 2002 Stock Incentive Plan.
- Following this transaction, Kevin A. Price beneficially owns 3,951 shares of Common Stock.
- Additionally, Kevin A. Price acquired 3,061 stock options on October 15, 2025, with an exercise price of $127.52.
- These newly acquired stock options become exercisable on October 15, 2026, and expire on October 14, 2035.
- The filing also details several tranches of previously held stock options with various exercise prices and expiration dates, totaling 15,405 derivative securities.
Sentiment
Score: 6
Explanation: The filing reports a routine equity grant to a director, which is a standard practice to align interests. This is generally viewed as a neutral to slightly positive event, as it reinforces commitment without indicating any significant operational or financial changes.
Positives
- The equity grant aligns the interests of Director Kevin A. Price with those of the shareholders, as his compensation is tied to the company's stock performance.
- The award is made under an established and approved incentive plan (Amended and Restated 2002 Stock Incentive Plan), indicating structured corporate governance regarding executive and director compensation.
Future Outlook
The restricted stock units are subject to vesting, and the newly acquired stock options will become exercisable on October 15, 2026, indicating future equity-based compensation events for the director.
Industry Context
Equity grants to directors, including restricted stock units and stock options, are a common practice across publicly traded companies to incentivize long-term performance and align leadership interests with shareholder value. This transaction is consistent with standard compensation practices in the financial services and human capital management industries.
Comparison to Industry Standards
- The use of restricted stock units (RSUs) and stock options for director compensation is a widely adopted practice among S&P 500 companies, including peers in the business services sector.
- The vesting schedule for RSUs and the exercisability period for options are typical for long-term incentive plans designed to retain directors and encourage sustained performance.
- The specific number of units and options granted would typically be benchmarked against director compensation at comparable companies in terms of market capitalization, revenue, and industry sector, though such comparative data is not provided in this filing.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Plan Utilization | The equity award was made pursuant to the company's Amended and Restated 2002 Stock Incentive Plan, demonstrating the ongoing use of an established governance framework for director compensation. | 10/15/2025 | Reinforces the company's commitment to performance-based compensation and aligns director incentives with long-term shareholder value. |
Stakeholder Impact
- Shareholders: The equity grant aligns the director's financial interests with shareholder value, potentially encouraging decisions that benefit long-term stock performance.
- Employees: No direct impact on employees is indicated by this director-specific compensation filing.
Next Steps
- Vesting of the 725 restricted stock units according to the terms of the Amended and Restated 2002 Stock Incentive Plan.
- The 3,061 newly acquired stock options will become exercisable on October 15, 2026.
Key Dates
| Date | Description |
|---|---|
| 07/15/2022 | Date exercisable for 5,075 stock options with an exercise price of $112.67, expiring 07/14/2031. |
| 07/15/2023 | Date exercisable for 3,027 stock options with an exercise price of $115, expiring 07/14/2032. |
| 07/15/2024 | Date exercisable for 3,382 stock options with an exercise price of $120.86, expiring 07/14/2033. |
| 07/15/2025 | Date exercisable for 3,351 stock options with an exercise price of $121.63, expiring 07/14/2034. |
| 10/15/2025 | Date of transaction for the acquisition of 725 restricted stock units and 3,061 stock options. |
| 10/17/2025 | Signature date of the reporting person's attorney-in-fact. |
| 10/15/2026 | Date exercisable for 3,061 newly acquired stock options with an exercise price of $127.52. |
| 07/15/2026 | Date exercisable for 670 stock options with an exercise price of $140.68, expiring 07/14/2035. |
| 10/14/2035 | Expiration date for 3,061 newly acquired stock options. |
Recommendation
holdThis Form 4 reports a routine equity grant to a director, which is a standard compensation practice. It does not present new information that would significantly alter the investment thesis for Paychex Inc. The grant aligns the director's interests with shareholders but does not indicate a material change in company performance or outlook, thus warranting a 'hold' recommendation based solely on this filing.
Keywords
Paychex, PAYX, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Executive Compensation, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.